Literature DB >> 25515722

Breast cancer treatment delays in a majority minority community: is there a difference?

Helen M Parsons1, Kate I Lathrop2, Susanne Schmidt2, Marcela Mazo-Canola2, Jessica Trevino-Jones2, Heather Speck2, Anand B Karnad2.   

Abstract

PURPOSE: Recent studies from large nationwide cancer databases have consistently shown that Hispanic women with breast cancer have delays in treatment initiation compared with non-Hispanic white women. However, time to treatment initiation has not been studied in a community where Hispanics are the majority. PATIENTS AND METHODS: We conducted a retrospective, observational study of 362 female patients with breast cancer treated at a large National Cancer Institute (NCI) -designated cancer center with a largely Hispanic population. We examined the relationship between race/ethnicity and time from mammogram to biopsy as well as time from biopsy to treatment initiation using Kaplan-Meier analyses and multivariable Cox proportional hazards regression.
RESULTS: Half of the female patients with breast cancer were of Hispanic descent (50.0%; n = 181). Hispanic patients were more likely to be obese, have an Eastern Cooperative Oncology Group functional status ≥ 1, and have higher histologic grade disease (all P ≤ .05); no differences in American Joint Committee on Cancer stage at diagnosis were observed. After comprehensive adjustment for demographic and clinical characteristics, we found no significant differences between Hispanic versus non-Hispanic white patients in time from mammogram to biopsy (hazard ratio [HR], 0.91; 95% CI, 0.68 to 1.21) or time from biopsy to treatment (HR, 1.13; 95% CI, 0.69 to 1.88).
CONCLUSION: Hispanic women and Non-Hispanic white women with breast cancer treated at an NCI-designated cancer center had similar times to biopsy and treatment initiation. These findings suggest that in majority minority communities with large cancer centers, racial disparities can be reduced. With a growing Hispanic population throughout the United States, future studies should examine the long-term impact on improved breast cancer survival in this population.
Copyright © 2014 by American Society of Clinical Oncology.

Entities:  

Mesh:

Year:  2014        PMID: 25515722      PMCID: PMC4365298          DOI: 10.1200/JOP.2014.000141

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN: 1554-7477            Impact factor:   3.840


  24 in total

Review 1.  Understanding racial disparities in cancer treatment and outcomes.

Authors:  Arden M Morris; Kim F Rhoads; Steven C Stain; John D Birkmeyer
Journal:  J Am Coll Surg       Date:  2010-07       Impact factor: 6.113

2.  Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology.

Authors:  N Krieger
Journal:  Am J Public Health       Date:  1992-05       Impact factor: 9.308

3.  Reducing disparities in breast cancer care: a daunting but essential responsibility.

Authors:  Rachel A Freedman; Eric P Winer
Journal:  J Natl Cancer Inst       Date:  2008-11-25       Impact factor: 13.506

4.  Correlates of worry about recurrence in a multiethnic population-based sample of women with breast cancer.

Authors:  Nancy K Janz; Sarah T Hawley; Mahasin S Mujahid; Jennifer J Griggs; Amy Alderman; Ann S Hamilton; John J Graff; Reshma Jagsi; Steven J Katz
Journal:  Cancer       Date:  2011-03-28       Impact factor: 6.860

5.  Breast cancer treatment experiences of Latinas in Los Angeles County.

Authors:  Steven J Katz; Paula M Lantz; Yvonne Paredes; Nancy K Janz; Angela Fagerlin; Lihua Liu; Dennis Deapen
Journal:  Am J Public Health       Date:  2005-10-27       Impact factor: 9.308

6.  Race and ethnicity are associated with delays in breast cancer treatment (2003-2006).

Authors:  Stacey A Fedewa; Stephen B Edge; Andrew K Stewart; Michael T Halpern; Nicole M Marlow; Elizabeth M Ward
Journal:  J Health Care Poor Underserved       Date:  2011-02

7.  Time to treatment for patients receiving BCS in a public and a private university hospital in Atlanta.

Authors:  Marina Mosunjac; Jaemin Park; Alexandra Strauss; George Birdsong; Victor Du; Monica Rizzo; Sheryl G A Gabram; Mary Jo Lund
Journal:  Breast J       Date:  2012-01-12       Impact factor: 2.431

8.  Race versus place of service in mortality among medicare beneficiaries with cancer.

Authors:  Tracy Onega; Eric J Duell; Xun Shi; Eugene Demidenko; David C Goodman
Journal:  Cancer       Date:  2010-06-01       Impact factor: 6.860

9.  Trends in racial and age disparities in definitive local therapy of early-stage breast cancer.

Authors:  Rachel A Freedman; Yulei He; Eric P Winer; Nancy L Keating
Journal:  J Clin Oncol       Date:  2008-12-22       Impact factor: 44.544

10.  Race and surgical outcomes: it is not all black and white.

Authors:  Nestor F Esnaola; Bruce L Hall; Patrick W Hosokawa; John Z Ayanian; William G Henderson; Shukri F Khuri; Michael J Zinner; Selwyn O Rogers
Journal:  Ann Surg       Date:  2008-10       Impact factor: 12.969

View more
  4 in total

1.  The "Empowering Latinas to Obtain Breast Cancer Screenings" study: Rationale and design.

Authors:  Yamile Molina; Liliana G San Miguel; Lizeth Tamayo; Casandra Robledo; Carola Sánchez Díaz; Araceli Lucio; Nora Coronado; Carol Estwing Ferrans
Journal:  Contemp Clin Trials       Date:  2018-05-25       Impact factor: 2.226

2.  Cost Analysis of a Surgical Consensus Guideline in Breast-Conserving Surgery.

Authors:  Jennifer Yu; Leisha C Elmore; Amy E Cyr; Rebecca L Aft; William E Gillanders; Julie A Margenthaler
Journal:  J Am Coll Surg       Date:  2017-04-14       Impact factor: 6.113

3.  Has racial difference in cause-specific death improved in older patients with late-stage breast cancer?

Authors:  J Ning; S Peng; N Ueno; Y Xu; Y Shih; M Karuturi; S Giordano; Y Shen
Journal:  Ann Oncol       Date:  2015-07-28       Impact factor: 32.976

4.  Factors Associated With Use of High-Cost Agents for the Treatment of Metastatic Non-Small Cell Lung Cancer.

Authors:  Cathy J Bradley; Megan Eguchi; Marcelo C Perraillon
Journal:  J Natl Cancer Inst       Date:  2020-08-01       Impact factor: 13.506

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.